KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Minority Interest (2016 - 2018)

Vertex Pharmaceuticals (VRTX) has 8 years of Minority Interest data on record, last reported at $28.4 million in Q3 2018.

  • For Q3 2018, Minority Interest rose 133.13% year-over-year to $28.4 million; the TTM value through Sep 2018 reached $28.4 million, up 133.13%, while the annual FY2017 figure was $13.7 million, 92.44% down from the prior year.
  • Minority Interest reached $28.4 million in Q3 2018 per VRTX's latest filing, down from $29.8 million in the prior quarter.
  • Across five years, Minority Interest topped out at $196.0 million in Q2 2017 and bottomed at $12.2 million in Q3 2017.
  • Average Minority Interest over 5 years is $112.1 million, with a median of $153.7 million recorded in 2015.
  • Peak YoY movement for Minority Interest: soared 654.87% in 2016, then tumbled 93.49% in 2017.
  • A 5-year view of Minority Interest shows it stood at $21.2 million in 2014, then soared by 625.6% to $153.7 million in 2015, then increased by 18.19% to $181.6 million in 2016, then plummeted by 92.44% to $13.7 million in 2017, then soared by 106.64% to $28.4 million in 2018.
  • Per Business Quant database, its latest 3 readings for Minority Interest were $28.4 million in Q3 2018, $29.8 million in Q1 2018, and $13.7 million in Q4 2017.